Tag Archives: About

Spending on Medicines In and Post-COVID Say a Lot About Patients and Larger Healthcare Trends – an IQVIA Update

Spending on medicines, globally, will rebound this year and rise above pre-pandemic levels through 2025. Between 2021 and 2025, the annual growth global growth rate for prescription drugs spending is expected to range from 3% to 6%, a $ 1.6 trillion bill for the worlds’s total Rx medicines market. That relatively low single-digit growth rate… Read More »

What you need to know about coronavirus today

A version of this story appeared in the September 16 edition of CNN’s Coronavirus: Fact vs. Fiction newsletter. Sign up here to receive the need-to-know headlines every weekday. At an ABC town hall in the crucial swing state of Pennsylvania, the President hit back at a question over his remarks to renowned journalist Bob Woodward… Read More »

Ask the Doctor: D. Todd Detar, DO, Answers Questions about Osteopathic Medicine and His Role in the Community

D. Todd Detar, DO Q. What attracted you to medicine? A. While studying health education at the University of Delaware, a college sports injury ended my life’s dream of becoming an NFL player. One of my coaches saw an opportunity for me to work as a trainer for the Philadelphia Phillies, and over time, I… Read More »

Merck scraps Keytruda lung cancer trial adding Bristol Myers’ Yervoy. What about the Opdivo combo?

Merck’s Keytruda is without doubt the king in previously untreated non-small cell lung cancer, but the company wanted to see whether adding another immuno-oncology agent from rival Bristol Myers Squibb would offer additional benefit. Turns out, doing that adds more harm and no good. Merck decided to stop adding Bristol Myers’ CTLA-4 inhibitor Yervoy to Keytruda in… Read More »